The CSF receptor inhibitor PLX3397 blocks CSF-1R tyrosine kinase activity and, while it doesn’t reduce TAM infiltration, it shifts TAMs toward the M1 phenotype, inhibiting tumor growth [251]. This evidence concerns the gene CSF1R and neoplasm.